Effect of mutations in rev gene of SIVmac on virus replication.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Effect of mutations in rev gene of SIVmac on virus replication.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S123-8. Unique Identifier : AIDSLINE MED/95169467
Aavik E; Hakkarainen K; Krohn KJ; Institute of Biomedical Sciences, University of Tampere, Finland.

Abstract: The functional activity of SIVmac251 Rev was altered by introducing amino acid changes inside and chain termination mutations after the Rev response element-binding region (RBR) of the protein. The effects of specific mutations were evaluated by transfecting proviral DNAs into the HeLa cell line and into HeLa cells constitutively expressing either HIV-1 Rev or HTLV-1 Rex proteins. Cell-free supernatants from these transient expression assays were further characterized by infecting CD4-positive lymphoid cell lines H9 and MT-4, the latter abortively infected with HTLV-1, and human peripheral blood mononuclear cells. These results together with the data from cotransfection experiments show that SIV can be attenuated up to 95% by introducing changes into the arginine-rich domain, RBR, of Rev. These recessive mutations were efficiently complemented in trans by HIV-1 Rev, SIV Rev, and HTLV-I Rex proteins. In contrast, the mutants of Rev protein that had a chain termination after RBR were trans-dominant negative and could not be trans-complemented with any of these three regulatory proteins. When additional mutations were inserted into the RBR of these trans-dominantly negative Rev proteins, complementation was obtained again.

Keywords: Amino Acid Sequence Cell Line Gene Products, rev/GENETICS *Genes, rev Hela Cells Human Molecular Sequence Data *Mutation Support, Non-U.S. Gov't SAIDS Vaccines/ISOLATION & PURIF SIV/*GENETICS/PHYSIOLOGY Transfection Vaccines, Attenuated/ISOLATION & PURIF Vaccines, Synthetic/ISOLATION & PURIF Virus Replication/*GENETICS JOURNAL ARTICLE
950630
M9561149

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .